drugset
drugset / Trial / NCT00028873

R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy

NCT00028873 ↗

Phase 2 Completed 35 enrolled European Organisation for Research and Treatment of Cancer - EORTC
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining R101933 with paclitaxel or docetaxel may reduce resistance to the drug and allow the tumor cells to be killed. PURPOSE: Phase II trial to study the effectiveness of combining R101933 with either paclitaxel or docetaxel in treating patients who have metastatic breast cancer that has not responded to previous chemotherapy.

Timeline

Start
2001-09
Primary completion
2002-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule — Intravenous
Subject Paclitaxel Small molecule — Intravenous
Subject laniquidar Small molecule — Intravenous

Indications

breast cancer